BPC-157

A synthetic peptide derived from a protective gastric-juice protein sequence, researched for tissue repair, inflammation, and recovery following injury.

Typical bottle: 10 mg

Research note: Much of the evidence surrounding BPC-157 comes from animal and laboratory research. High-quality human clinical data remain limited, so preclinical findings should not be assumed to translate directly to humans.

What It Is

BPC-157 is a synthetic peptide derived from a protective sequence associated with gastric juice proteins. It has been extensively studied in preclinical research for its potential effects on tissue repair, inflammation, blood-vessel formation, and recovery following injury.

Research has looked at BPC-157 across several types of tissue, including tendons, ligaments, muscles, nerves, skin, and the gastrointestinal tract. One area of interest is its potential influence on angiogenesis — the formation of new blood vessels — which may help support the delivery of oxygen and nutrients to areas undergoing repair.

BPC-157 has also been investigated for its effects on inflammatory signaling and cellular processes involved in tissue recovery. This combination of potential repair-supporting and inflammation-modulating activity is why BPC-157 is commonly included in recovery-focused research protocols.

Who May Benefit

Tendon and ligament recovery
Muscle recovery following injury or overuse
Joint and connective-tissue recovery
Recovery following surgery
Soft-tissue healing
Inflammation-related discomfort
Gastrointestinal tissue research
General recovery and tissue-repair protocols

What to Expect

BPC-157 is generally approached as a recovery-focused compound used consistently over a period of weeks, rather than something expected to produce an immediate change.

Research interest centers around potential improvements in tissue recovery, inflammation, mobility, and overall healing processes. Some report less discomfort, improved mobility, and faster recovery from training-related or soft-tissue issues — these reports are anecdotal and should not be confused with established clinical outcomes.

The underlying injury, severity, training load, nutrition, sleep, and rehabilitation strategy will all influence recovery. BPC-157 should complement — not replace — appropriate rehabilitation and medical care when necessary.

What to Pair It With

TB-500

Commonly researched alongside BPC-157 for broader soft-tissue recovery through a different but complementary repair pathway.

GHK-Cu

Investigated for tissue remodeling, wound healing, and connective-tissue processes.

ARA-290

Research focuses on tissue protection, nerve health, and inflammation modulation.

Cartalax

A recovery-focused peptide commonly incorporated into protocols targeting joints and connective tissue.

Reconstitution

Vial

10 mg

Diluent

2 mL Bac. Water

Final Concentration

5 mg/mL

10 units = 500 mcg20 units = 1 mg

Suggested Research Dosing Strategy

Maintenance / Lower Range

500 mcg (10 units)

Once daily · subcutaneous · 5 days ON / 2 days OFF or every other day.

Advanced / Loading Range

1 mg (20 units)

Once daily for 10 consecutive days, then step down to 500 mcg (10 units) on a 5 ON / 2 OFF schedule.

Suggested research cycle: 8–12 weeks or until the research objective is reached. Estimated quantity for an 8–16 week cycle: approximately 3–8 × 10 mg vials.

Administration Notes

Subcutaneous administration is commonly used. For localized research applications, administration may be performed in the general subcutaneous area surrounding the region being researched.

Do not inject directly into an injured tendon, joint, or other damaged tissue. For a more systemic approach, the abdomen is a common subcutaneous administration area.

Evening administration may be incorporated into recovery-focused protocols. A fasted state is sometimes used, though there is limited evidence that fasting is required for effect.

Research Considerations

BPC-157 is one of the more widely discussed recovery peptides because preclinical research has investigated its potential effects across multiple tissue types and repair pathways — including angiogenesis, inflammatory signaling, cellular migration, and tissue repair.

The distinction between preclinical research and established human evidence is important. BPC-157 is not an FDA-approved treatment for injuries, pain, inflammation, or gastrointestinal disease, and robust human clinical evidence remains limited.

Have a specific question about BPC-157? Chat with Pulse, Signal IQ’s free AI research assistant — ask about mechanisms, stacking, or how it compares to other compounds.

For research purposes only. Not approved for human use. This information is provided for educational and research purposes and is not medical advice. Signal IQ does not sell peptides.

All Peptides by Goal